Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Umbrella Trial for Unresectable Stage III NSCLC With Rare Mutations
NCT06563999Phase 2Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Nov 2024
- Primary completion
- Nov 2027
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label trial of sunvozertinib, crizotinib, pralsetinib, larotrectinib, savolitinib and 5 more in non-small cell lung cancer (NSCLC) (9 arms), sponsored by Sun Yat-sen University. Primary endpoint: Resectability rate at 6 months. Started Nov 2024; status: recruiting.
02
Drugs
sunvozertinibcrizotinibpralsetiniblarotrectinibsavolitinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06563999.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06563999.